Literature DB >> 8623456

Cost-containment strategies in transplantation: the utility of cyclosporine-ketoconazole combination therapy.

O Odocha1, B Kelly, S Trimble, C Murigande, R M Toussaint, C O Callender.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8623456

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  6 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 2.  The clinical and economic potential of cyclosporin drug interactions.

Authors:  J E Martin; A J Daoud; T J Schroeder; M R First
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

3.  Combining cytochrome P-450 3A4 modulators and cyclosporine or everolimus in transplantation is successful.

Authors:  Fernando González; Ricardo Valjalo
Journal:  World J Transplant       Date:  2015-12-24

Review 4.  The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.

Authors:  T E Jones
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

5.  The use of a cyclosporin-ketoconazole combination: making renal transplantation affordable in developing countries.

Authors:  T Gerntholtz; M D Pascoe; J F Botha; J Halkett; D Kahn
Journal:  Eur J Clin Pharmacol       Date:  2004-04-09       Impact factor: 2.953

Review 6.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.